NCT02295059 2026-04-03
Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention
City of Hope Medical Center
Phase NA Active not recruiting
Clinical Trials
11 trialsNCT01881048 2026-01-29
Window of Opportunity Study Targeting the Inflammatory Milieu
University of Colorado, Denver
Phase EARLY_PHASE1 Completed
NCT03831178 2025-06-26
DHA-WIN
AHS Cancer Control Alberta
Phase 2 Active not recruiting
NCT06928701 2025-04-15
NEOMET
University of Eastern Piedmont
Phase NA Recruiting
NCT02538484 2023-07-17
Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects
The University of Texas Health Science Center at San Antonio
Phase EARLY_PHASE1 Completed
NCT02831582 2023-02-27
Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT02278965 2022-08-17
Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
Columbia University
Phase 1 Completed
NCT02101970 2022-01-24
Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women
University of Kansas Medical Center
Phase NA Completed
NCT02517502 2022-01-24
Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy
University of Kansas Medical Center
Phase EARLY_PHASE1 Completed
NCT01849250 2021-12-28
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
National Cancer Institute (NCI)
Phase 2 Completed
NCT02352779 2017-08-08
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
University of Rochester
Phase NA Completed